Bicycle Therapeutics (BCYC) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pyxis Oncology (PYXS) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 31.6% versus a loss of 53.9%. Over five years, PYXS leads with a -83.1% price change compared with -93.6% for BCYC. Bicycle Therapeutics is the larger company by market cap ($266.7 million vs $237.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | PYXS |
|---|---|---|
| Share price | $3.81 | $1.99 |
| Market cap | $266.67M | $237.72M |
| 1-day change | +2.14% | -1.00% |
| YTD return | -46.19% | +73.04% |
| 1-year return | -53.87% | -31.62% |
| 5-year return | -93.57% | -83.09% |
| EPS (TTM) | $-2.73 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.10 | $5.55 |
| 52-week low | $3.33 | $1.03 |
| Distance from 52-week high | -58.13% | -64.14% |
| Analyst consensus | none | none |
| Avg. price target upside | +149.34% | +335.68% |
| Average volume | 387.29K | 1.26M |
| Shares outstanding | 50.55M | 119.46M |
| Employees | 288 | 56 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYXS has outperformed BCYC by 22.3 percentage points over the past year.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Healthcare · Biotechnology · 288 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Healthcare · Biotechnology · 56 employees
BCYC vs PYXS FAQ
Which is bigger, Bicycle Therapeutics or Pyxis Oncology?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $266.67M compared with $237.72M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, BCYC or PYXS?
PYXS returned -31.62% over the past 12 months, compared with -53.87% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.